Copyright (c) 2025 Documentos de trabajo ECISA

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Inmunotherapy, Cancer, Genetics, and Clinical Microbiology: Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells, ABO Phenotype, and Antimicrobial Resistance
Inmunotherapy has revolutionized cancer treatment, and one of the most promising strategies is the use of natural killer cells modified with chimeric antigen receptors (CAR-NK). These cells combine the specificity of CAR receptors with the innate cytotoxic capacity of NK cells, offering an effective and safe alternative to other immunotherapeutic treatments. Additionally, the ABO phenotype has been associated with various hematological and non-hematological diseases, suggesting a relevant role of genetics in disease predisposition. Moreover, antimicrobial resistance has become a critical issue in clinical microbiology, requiring new strategies to combat resistant infections. This paper analyzes recent advances in CAR-NK therapy, the impact of the ABO phenotype on hematological diseases, and research on antimicrobial resistance, including new therapeutic approaches and experimental models.